Is atrial remodeling a viable target for prevention of atrial fibrillation recurrence?
Nattel
Stanley
S
D000200:Action Potentials / Q000187:drug effects*; D000284:Administration, Oral; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology* / Q000517:prevention & control / Q000628:therapy; D002908:Chronic Disease; D004554:Electric Countershock; D006325:Heart Atria / Q000187:drug effects* / Q000503:physiopathology*; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D055502:Secondary Prevention; D013015:Sotalol / Q000008:administration & dosage*; D016896:Treatment Outcome; D020257:Ventricular Remodeling / Q000187:drug effects*
D000889:Anti-Arrhythmia Agents; D013015:Sotalol